Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

October 10, 2025

Study Completion Date

March 30, 2026

Conditions
Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

digestive enzymes

A jar or single-dose sachets containing the digestive enzymes in the form of powder will be provided to each patient at the study entry. Patients will be instructed to use the powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. Participants will be asked to return the jar or the single dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly. Participants will be asked to return the jar or the single-dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned.

Trial Locations (2)

12462

RECRUITING

Attikon University General Hospital, Athens

Unknown

RECRUITING

Attikon University General Hospital, Chaïdári

All Listed Sponsors
lead

Attikon Hospital

OTHER